Similar articles

• Epidermal growth factor receptor inhibitors: current status and future directions.

  Chen HX, Cleck JN, Coelho R, Dancey JE. Chen HX, et al. Curr Probl Cancer. 2009 Jul-Aug;33(4):245-94. doi: 10.1016/j.currproblcancer.2009.10.002. Curr Probl Cancer. 2009. PMID: 20082842 Review. No abstract available.
• Anti-epidermal growth factor receptor strategies for advanced breast cancer.

  Campos SM. Campos SM. Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040. Cancer Invest. 2008. PMID: 18853311 Review. No abstract available.
• The HER3/ErbB3 receptor: a promising target in cancer drug therapy.

  Desbois-Mouthon C. Desbois-Mouthon C. Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):255-9. doi: 10.1016/j.gcb.2010.03.002. Epub 2010 Apr 24. Gastroenterol Clin Biol. 2010. PMID: 20418034 No abstract available.
• Molecularly targeted therapy: when to stop and when to continue?

  Hirsch FR, Mok TS, Borges V, Bunn PA Jr. Hirsch FR, et al. Lancet Oncol. 2010 Aug;11(8):709-11. doi: 10.1016/S1470-2045(10)70128-5. Lancet Oncol. 2010. PMID: 20570560 No abstract available.
• Targeted therapies: aiming for the bull's-eye.

  Gaguski ME. Gaguski ME. ONS Connect. 2007 Jul;22(7):8-12. ONS Connect. 2007. PMID: 17694778 No abstract available.